🕵️ JADE Biosciences, Inc. ($JBIO)
SEC insider & ownership activity, last 12 months · CIK 1798749 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. Fairmount Healthcare Fund II L.P. added 14.9% → 16.2%. No red-flag 8-Ks in the window.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20.0% | 13D | Jun 5, 2026 | filing ↗ | |
| Tomas Kiselak | 20.0% | 13D | Jun 5, 2026 | filing ↗ | |
| Peter Evan Harwin | 20.0% | 13D | Jun 5, 2026 | filing ↗ | |
| Fairmount Healthcare Fund II L.P. | 16.2% | 13D | Jun 5, 2026 | filing ↗ | |
| FMR LLC | 14.7% | 13G | Jun 6, 2025 | filing ↗ | |
| Abigail P. Johnson | 14.7% | 13G | Jun 6, 2025 | filing ↗ | |
| Janus Henderson Group Ltd. | 10.6% | 13G | Jul 8, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Co-Investment Holdings III, LLC | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Management III, LLC | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| VHCP Management EG, LLC | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Nimish Shah | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Bong Y. Koh | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Bong Y Koh | 9.9% | 13G | May 5, 2025 | filing ↗ | |
| RA Capital Management, L.P. | 7.0% | 13G | Oct 16, 2025 | filing ↗ | |
| Peter Kolchinsky | 7.0% | 13G | Oct 16, 2025 | filing ↗ | |
| Rajeev Shah | 7.0% | 13G | Oct 16, 2025 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 7.0% | 13G | Oct 16, 2025 | filing ↗ | |
| Bellevue Group AG | 6.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Bellevue Asset Management AG | 6.8% | 13G | Feb 17, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors LP | 5.1% | 13G | Jul 17, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors GP LLC | 5.1% | 13G | Jul 17, 2026 | filing ↗ | |
| Senai Asefaw, M.D. | 5.1% | 13G | Jul 17, 2026 | filing ↗ | |
| Paradigm Biocapital International Fund Ltd. | exited | 13G | Jul 17, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Jun 29, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 25, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 25, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 25, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 8, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 8, 2026 | filing ↗ |
| Other events (8.01) | Jun 3, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 3, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 1, 2026 | filing ↗ |
| Other events (8.01) | Jun 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 1, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 18, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 31, 2026 | filing ↗ |
| Earnings (2.02) | Mar 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 6, 2026 | filing ↗ |
| Earnings (2.02) | Jan 5, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 5, 2026 | filing ↗ |
| Material agreement (1.01) | Dec 13, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Dec 13, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Dec 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 13, 2025 | filing ↗ |
| Earnings (2.02) | Nov 13, 2025 | filing ↗ |
| Other events (8.01) | Nov 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 13, 2025 | filing ↗ |
| Material agreement (1.01) | Oct 3, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Oct 3, 2025 | filing ↗ |